Dr. James A. Fagin

Dr. James A. Fagin, MD, is an internationally acclaimed endocrinologist and physician-scientist specializing in thyroid cancer. He leads the Endocrinology Service at Memorial Sloan Kettering Cancer Center and holds the prestigious Larry Norton Chair in Cancer Research. After earning his medical degree from the University of Buenos Aires, Dr. Fagin completed residency and fellowship training in internal medicine and endocrinology, establishing a career dedicated to advancing the understanding and treatment of endocrine malignancies. He is board-certified in Endocrinology, Diabetes & Metabolism and Internal Medicine, and is recognized for delivering expert, compassionate care to patients with complex thyroid cancer diagnoses.

A trailblazer in translational research, Dr. Fagin’s work has defined many of the genetic drivers of thyroid cancer, particularly mutations in the BRAF and RAS genes. His laboratory has been instrumental in identifying mechanisms of resistance to targeted therapies, and his research has led to clinical trials that brought new precision treatments to patients with advanced or refractory thyroid cancer. Dr. Fagin has published widely in high-impact journals, and his contributions have shaped how clinicians understand and treat the molecular underpinnings of thyroid malignancies.

Beyond his research and clinical expertise, Dr. Fagin is a revered educator and thought leader. He has served in leadership roles within the American Thyroid Association and the Endocrine Society, and he has received numerous awards for his contributions to endocrine oncology, including election to the American Society for Clinical Investigation and the Association of American Physicians. With a career devoted to integrating groundbreaking science with patient care, Dr. Fagin remains at the forefront of thyroid cancer innovation and discovery.